Shots:

• Takeda is issuing a recall for all doses of Natpara for injection (25/50/75/100 mcg) in the US after the discussion with US FDA due to the potential for rubber particulate instigating from the rubber septum of the NATPARA cartridge
• Takeda is advising patients to consult with their healthcare providers about the discontinuation of Natpara treatment as it may lead to severe hypocalcemia resulting in serious health consequences
• Natpara is a recombinant human protein with 84 amino acid sequence of endogenous parathyroid hormone. Healthcare providers can contact Takeda for queries related to recall at +1-800-828-2088 & select Option 2 and patients can contact OnePath at +1-866-888-0660

Click here to­ read full press release/ article

Ref: Takeda | Image: Takeda